Glasdegib Maleate and Matzim LA
Determining the interaction of Glasdegib Maleate and Matzim LA and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:DilTIAZem may increase the blood levels of glasdegib in some patients. High levels of glasdegib can increase the risk of an irregular heart rhythm that may be serious and potentially life-threatening, although it is a relatively rare side effect. You may be more susceptible if you have a heart condition called congenital long QT syndrome, other cardiac diseases, conduction abnormalities, or electrolyte disturbances (for example, magnesium or potassium loss due to severe or prolonged diarrhea or vomiting). The risk and/or severity of other side effects may also increase, including nausea, decreased appetite, constipation, mouth sores, muscle pain, shortness of breath, swelling of arms or legs, and impaired bone marrow function resulting in low numbers of different types of blood cells. You may also be more likely to develop anemia, bleeding problems, or fever and infections due to low blood cell counts. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact, or you may need a dose adjustment or more frequent monitoring to safely use both medications. You should seek immediate medical attention if you develop sudden dizziness, lightheadedness, fainting, shortness of breath, or heart palpitations during treatment with glasdegib. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:MONITOR: Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of glasdegib, which is primarily metabolized by the isoenzyme. When glasdegib was coadministered with ketoconazole, a potent CYP450 3A4 inhibitor, glasdegib peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 1.4- and 2.4-fold, respectively, compared to administration of glasdegib alone. The interaction has not been studied with other, less potent CYP450 3A4 inhibitors.
MANAGEMENT: Caution is advised when glasdegib is used with CYP450 3A4 inhibitors. Patients should be monitored for adverse effects such as QT interval prolongation, anemia, febrile neutropenia, thrombocytopenia, hemorrhage, edema and mucositis, and the glasdegib dosage adjusted as necessary in accordance with the product labeling.
- "Product Information. Daurismo (glasdegib)." Pfizer U.S. Pharmaceuticals Group, New York, NY.
Generic Name: glasdegib
Brand name: Daurismo
Synonyms: Glasdegib
Generic Name: diltiazem
Brand name: Cardizem, Cartia XT, Dilacor XR, Dilt-CD, Diltia XT, Diltzac, Matzim LA, Taztia XT, Tiazac, Cardizem CD, Dilt-XR, Tiazac, Cardizem LA, Tiazac Extended Release Capsules
Synonyms: Matzim LA (Oral)
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Glasdegib Maleate-Mavenclad
- Glasdegib Maleate-Mavik
- Glasdegib Maleate-Mavyret
- Glasdegib Maleate-Maxair
- Glasdegib Maleate-Maxair Autohaler
- Glasdegib Maleate-Maxalt
- Matzim LA-Glatiramer Acetate
- Matzim LA-Glatiramer injection
- Matzim LA-Glatiramer Subcutaneous
- Matzim LA-Glatopa
- Matzim LA-Glatopa injection
- Matzim LA-Glecaprevir and pibrentasvir